190 related articles for article (PubMed ID: 32784543)
1. Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their "pH" Enotype?
Calò LA; Davis PA
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784543
[TBL] [Abstract][Full Text] [Related]
2. ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes.
Calò LA; Rigato M; Sgarabotto L; Gianesello L; Bertoldi G; Ravarotto V; Davis PA
Front Med (Lausanne); 2021; 8():647319. PubMed ID: 34017843
[TBL] [Abstract][Full Text] [Related]
3. Gitelman's and Bartter's Syndromes: From Genetics to the Molecular Basis of Hypertension and More.
Ravarotto V; Bertoldi G; Stefanelli LF; Nalesso F; Calò LA
Kidney Blood Press Res; 2022; 47(9):556-564. PubMed ID: 35858584
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathophysiology of Bartter's and Gitelman's syndromes.
Koulouridis E; Koulouridis I
World J Pediatr; 2015 May; 11(2):113-25. PubMed ID: 25754753
[TBL] [Abstract][Full Text] [Related]
5. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways.
Calò LA; Puato M; Schiavo S; Zanardo M; Tirrito C; Pagnin E; Balbi G; Davis PA; Palatini P; Pauletto P
Nephrol Dial Transplant; 2008 Sep; 23(9):2804-9. PubMed ID: 18344243
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension.
Calò LA; Schiavo S; Davis PA; Pagnin E; Mormino P; D'Angelo A; Pessina AC
J Hypertens; 2010 Jan; 28(1):111-8. PubMed ID: 19797979
[TBL] [Abstract][Full Text] [Related]
7. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes.
Calò LA; Pagnin E; Ceolotto G; Davis PA; Schiavo S; Papparella I; Semplicini A; Pessina AC
J Hypertens; 2008 May; 26(5):938-45. PubMed ID: 18398336
[TBL] [Abstract][Full Text] [Related]
8. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved?
Calò LA; Montisci R; Scognamiglio R; Davis PA; Pagnin E; Schiavo S; Mormino P; Semplicini A; Palatini P; D'Angelo A; Pessina AC
J Endocrinol Invest; 2009 Nov; 32(10):832-6. PubMed ID: 19605975
[TBL] [Abstract][Full Text] [Related]
9. ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications.
Calò LA; Schiavo S; Davis PA; Pagnin E; Mormino P; D'Angelo A; Pessina AC
J Nephrol; 2010; 23(4):472-7. PubMed ID: 20349406
[TBL] [Abstract][Full Text] [Related]
10. Miscellaneous non-inflammatory musculoskeletal conditions. Bartter's and Gitelman's diseases.
Favero M; Calò LA; Schiavon F; Punzi L
Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):637-48. PubMed ID: 22142744
[TBL] [Abstract][Full Text] [Related]
11. Bartter's and Gitelman's syndrome.
Seyberth HW; Weber S; Kömhoff M
Curr Opin Pediatr; 2017 Apr; 29(2):179-186. PubMed ID: 27906863
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes.
Calò LA; Maiolino G
J Endocrinol Invest; 2015 Jul; 38(7):711-6. PubMed ID: 25740064
[TBL] [Abstract][Full Text] [Related]
13. Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter's and Gitelman's syndromes, human models of endogenous angiotensin II signaling antagonism.
Calò LA; Davis PA; Rossi GP
J Hypertens; 2014 Nov; 32(11):2109-19; discussion 2119. PubMed ID: 25202962
[TBL] [Abstract][Full Text] [Related]
14. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
15. ACE2 and prognosis of COVID-19: Insights from Bartter's and Gitelman's syndromes patients.
Calò LA; Davis PA; Rigato M; Sgarabotto L
J Med Virol; 2020 Nov; 92(11):2308-2309. PubMed ID: 32374416
[No Abstract] [Full Text] [Related]
16. Reduced mRNA and protein content of rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes: relevance for the pathophysiology of hypertension.
Pagnin E; Semplicini A; Sartori M; Pessina AC; Calò LA
Am J Hypertens; 2005 Sep; 18(9 Pt 1):1200-5. PubMed ID: 16182110
[TBL] [Abstract][Full Text] [Related]
17. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
18. The Dietary Approach to the Treatment of the Rare Genetic Tubulopathies Gitelman's and Bartter's Syndromes.
Francini F; Gobbi L; Ravarotto V; Toniazzo S; Nalesso F; Spinella P; Calò LA
Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578838
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling.
Calò LA; Pagnin E; Davis PA; Sartori M; Semplicini A
Nephrol Dial Transplant; 2003 Aug; 18(8):1518-25. PubMed ID: 12897089
[TBL] [Abstract][Full Text] [Related]
20. Mutations in SLC12A3 and CLCNKB and Their Correlation with Clinical Phenotype in Patients with Gitelman and Gitelman-like Syndrome.
Lee JW; Lee J; Heo NJ; Cheong HI; Han JS
J Korean Med Sci; 2016 Jan; 31(1):47-54. PubMed ID: 26770037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
